MINT | Jotup

TraceLink MINT Awarded 2024 Supply Chain Visibility Solution of the Year by SupplyTech Breakthrough

Retrieved on:

Donnerstag, Juni 13, 2024

MINT, Health care, Patient, UPS, Acceleration, ArcBest, Management

On Opus, MINT enables the seamless exchange of information among partners -- regardless of the type or version of enterprise systems each party uses -- related to supply chain planning, external manufacturing, logistics, clinical supply, and more. It achieves this through the rapid onboarding, management, and integration of partners' systems and business processes with a pre-authenticated digital network of over 290,000 entities across the Healthcare and Life Sciences supply chain. Through this innovative approach, MINT creates the real-time, permissioned supply chain information required for companies to execute on their supply chain digitalization and AI/ML transformations.

Key Points:

BOSTON, June 13, 2024 /PRNewswire/ -- TraceLink, a leader in digital supply chain solutions, is proud to announce that it has been honored with the 2024 SupplyTech Breakthrough Award for Supply Chain Visibility Solution of the Year for its innovative Multienterprise Information Network Tower (MINT) solution.
This recognition highlights TraceLink's commitment to transforming global supply chains by providing enhanced visibility and connectivity through its MINT solution, powered by TraceLink's Opus platform, a low/no-code development environment for enabling supply chain teams to design and deploy multi-enterprise solutions with trading partners.
On Opus, MINT enables the seamless exchange of information among partners -- regardless of the type or version of enterprise systems each party uses -- related to supply chain planning, external manufacturing, logistics, clinical supply, and more.
Through this innovative approach, MINT creates the real-time, permissioned supply chain information required for companies to execute on their supply chain digitalization and AI/ML transformations.

TraceLink MINT Awarded 2024 Supply Chain Visibility Solution of the Year by SupplyTech Breakthrough

Retrieved on:

Donnerstag, Juni 13, 2024

MINT, Health care, Patient, UPS, Acceleration, ArcBest, Management

On Opus, MINT enables the seamless exchange of information among partners -- regardless of the type or version of enterprise systems each party uses -- related to supply chain planning, external manufacturing, logistics, clinical supply, and more. It achieves this through the rapid onboarding, management, and integration of partners' systems and business processes with a pre-authenticated digital network of over 290,000 entities across the Healthcare and Life Sciences supply chain. Through this innovative approach, MINT creates the real-time, permissioned supply chain information required for companies to execute on their supply chain digitalization and AI/ML transformations.

Key Points:

BOSTON, June 13, 2024 /PRNewswire/ -- TraceLink, a leader in digital supply chain solutions, is proud to announce that it has been honored with the 2024 SupplyTech Breakthrough Award for Supply Chain Visibility Solution of the Year for its innovative Multienterprise Information Network Tower (MINT) solution.
This recognition highlights TraceLink's commitment to transforming global supply chains by providing enhanced visibility and connectivity through its MINT solution, powered by TraceLink's Opus platform, a low/no-code development environment for enabling supply chain teams to design and deploy multi-enterprise solutions with trading partners.
On Opus, MINT enables the seamless exchange of information among partners -- regardless of the type or version of enterprise systems each party uses -- related to supply chain planning, external manufacturing, logistics, clinical supply, and more.
Through this innovative approach, MINT creates the real-time, permissioned supply chain information required for companies to execute on their supply chain digitalization and AI/ML transformations.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on:

Donnerstag, Mai 9, 2024

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points:

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
“We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
An IND submission is expected in the fourth quarter of 2024.
Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

MINT Accelerates US Growth with Key Appointments and New Partnerships, Welcoming Seasoned Strategist Federico Salvitti as VP of Growth

Retrieved on:

Mittwoch, Mai 8, 2024

Quotient, Strategic management, Thought, Partnership, ARM, MINT, Culture, Automation, IPO, IPSOS, Marketing, Advertising, Data management, Accenture, Female, Sales

Salvitti will report to MINT’s Chief Growth Officer Salvatore Internullo.

Key Points:

Salvitti will report to MINT’s Chief Growth Officer Salvatore Internullo.
Salvitti serves as a professor at New York University, where he teaches Marketing Fundamentals, Data Management Strategy, and Business Strategy.
MINT has also made strategic appointments across its product, sales, marketing and customer success departments, further fortifying its growth efforts in the U.S. One of these key appointments is Mark D’Andrea, who has joined MINT’s US growth team.
“MINT is building a dynamic team, harnessing diverse expertise and talent to provide invaluable insight that fuels our growth and innovation in the US.

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Retrieved on:

Donnerstag, Mai 9, 2024

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Key Points:

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field.
We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo.

PlatON Unveils State-of-the-art Web3 Payment Solutions at Money 20/20 Asia

Retrieved on:

Dienstag, April 23, 2024

Money, Fintech, Blockchain, MINT, Platon, Multimedia, Cryptocurrency

By converting deposits into blockchain-based tokens, deposit tokenization not only boosts asset liquidity but also offers more efficient and cost-effective solutions for cross-border payments and financial transactions.

Key Points:

By converting deposits into blockchain-based tokens, deposit tokenization not only boosts asset liquidity but also offers more efficient and cost-effective solutions for cross-border payments and financial transactions.
At Money 20/20 Asia, PlatON showcased cutting-edge technology that not only demonstrates its expertise in the fintech sector but also signifies a significant step forward in driving payment technology innovation.
PlatON presented two payment methods, QRPAY and ZKPAY, as part of its on-chain payment acquiring solutions.
We've not only made strides in deposit tokenization technology but also demonstrated our on-chain payment solutions' capabilities in cross-border payments and payment clearing network construction.

TraceLink Named Finalist in the Prestigious Business Transformation & Operational Excellence Awards 2024

Retrieved on:

Montag, April 22, 2024

Interoperability, PAI, Business transformation, Operational excellence, Once, MINT, Artificial intelligence, Patient, Organization, Management

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.

Key Points:

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.
The Business Transformation & Operational Excellence Awards stand as the most prestigious recognition across industries, honoring organizations that have achieved significant success in transforming their operations and innovating at the highest levels.
"We are honored to be named finalists in the Business Transformation & Operational Excellence Awards 2024," said Shabbir Dahod, President and CEO of TraceLink.
The winners of the Business Transformation & Operational Excellence Awards 2024 will be announced at the upcoming awards ceremony on May 9th.

TraceLink Named Finalist in the Prestigious Business Transformation & Operational Excellence Awards 2024

Retrieved on:

Montag, April 22, 2024

Interoperability, PAI, Business transformation, Operational excellence, Once, MINT, Artificial intelligence, Patient, Organization, Management

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.

Key Points:

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.
The Business Transformation & Operational Excellence Awards stand as the most prestigious recognition across industries, honoring organizations that have achieved significant success in transforming their operations and innovating at the highest levels.
"We are honored to be named finalists in the Business Transformation & Operational Excellence Awards 2024," said Shabbir Dahod, President and CEO of TraceLink.
The winners of the Business Transformation & Operational Excellence Awards 2024 will be announced at the upcoming awards ceremony on May 9th.

Midwest Institute for Nonsurgical Therapy (MINT) Now Offers Innovative Treatment for Enlarged Prostate

Retrieved on:

Donnerstag, April 18, 2024

Patient, Prostate, Risk, TURP, MINT, PAE, Medicare, Quality of life, BPH, Medical imaging

ST. LOUIS, April 18, 2024 /PRNewswire/ -- The Midwest Institute for Nonsurgical Therapy (MINT), a leading provider of minimally invasive medical procedures, is proud to announce the introduction of Prostate Artery Embolization (PAE) for the treatment of Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate.

Key Points:

ST. LOUIS, April 18, 2024 /PRNewswire/ -- The Midwest Institute for Nonsurgical Therapy (MINT), a leading provider of minimally invasive medical procedures, is proud to announce the introduction of Prostate Artery Embolization (PAE) for the treatment of Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate.
"We are thrilled to offer Prostate Artery Embolization, a nonsurgical treatment that significantly improves the quality of life for patients suffering from BPH," said Dr. Akinwande.
MINT is among the few practices in the Midwest to offer this innovative service, positioning itself as a leader in nonsurgical therapies.
Patients seeking more information about Prostate Artery Embolization or to schedule a consultation can visit www.mintstl.com or contact MINT at 314 255 2204.

MINT Welcomes Shelley Zalis to Advisory Board

Retrieved on:

Donnerstag, April 4, 2024

Quotient, Culture, Organization, IPSOS, Growth, Female, Intelligence, General partnership, Knowledge, Research, ARM, Fortune 500, MINT, Advertising, Management

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- MINT , the global enterprise software solution for advertising resource management (ARM), announced the addition of industry heavyweight Shelley Zalis , Founder and CEO of The Female Quotient to its advisory board.

Key Points:

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- MINT , the global enterprise software solution for advertising resource management (ARM), announced the addition of industry heavyweight Shelley Zalis , Founder and CEO of The Female Quotient to its advisory board.
A research pioneer and well-known advocate for women’s equality, Zalis will provide strategic guidance and industry expertise for MINT.
Zalis is the newest addition to MINT’s expansive list of industry experts across its advisory board and board of directors, including Joe Zawadzki, General Partner at AperiamVentures, and known advertising expert.
“The addition of Shelley Zalis to MINT's advisory board marks a significant milestone in our journey towards driving digital transformation in advertising,” stated Lorenzo Larini, CEO of MINT.